MESO Nasdaq update, page-280

I think Taimoor164 makes a fair point for exactly the reasons you have mentioned col69. As you have said, the current share price really only reflects the likely sales generated by Ryoncil if/when approved. While I wouldn’t want to see large gaps created by a rapid share price rise due to the recent announcement, I am surprised to see meso trend downwards on the 2nd day post announcement. As a health care practitioner I have a comprehensive understanding of the mechanism of action for mesoblasts stem cell therapies and am 100% certain that the vast majority of mesoblasts therapies will have positive results, however the underlying potential of this stock is not being reflected in the share price and I can see why some are frustrated or confused. I believe this is predominantly due to a general lack of pathophysiological knowledge surrounding stem cell therapy among the vast majority of investors and just using this company as a short term/day trading stock. hoping to see the potential of this stock and it’s treatments publicised more widely to get more investors on-board.